TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15848326

Group type: EXPERIMENTAL
Intervention: Triflusal (600mg/d)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Acenocoumarol (target INR 2.0‐3.0)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Triflusal
Number of subjects: 193

Group type: COMPARATOR
Intervention: Acenocoumarol
Number of subjects: 193
Study: 11502777

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone therapy (32 patients treated)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone therapy (in responders)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo treatment (in responders)
Number of subjects: 37
Study: 9266258

Group type: COMPARATOR
Intervention: Whole blood cultures (WBC) stimulated with lipopolysaccharide (LPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole blood cultures (WBC) stimulated with whole killed Salmonella typhimurium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole blood cultures (WBC) stimulated with Staphylococcus aureus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole blood cultures (WBC) stimulated with concanavalin A (ConA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole blood cultures (WBC) stimulated with LPS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole blood cultures (WBC) stimulated with other bacterial components
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole blood cultures (WBC)
Number of subjects: 0
Study: 7508066

Group type: EXPERIMENTAL
Intervention: diet and fluid plus indapamide 2.5 mg/day (group B)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: diet and fluid plus indapamide 2.5 mg/day plus allopurinol 300 mg/day (group C)
Number of subjects: 75

Group type: COMPARATOR
Intervention: diet and fluid (group A)
Number of subjects: 75
Study: 3106449

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium Cromoglycate (SCG) (10 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (200 micrograms)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2685081

Group type: EXPERIMENTAL
Intervention: Amiodarone (200 mg every 8 h for 2 weeks, then 200 mg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 31976548

Group type: EXPERIMENTAL
Intervention: Tetramethylpyrazine (TMP) 100 mg·kg‐1 ·day‐1 in animal models (Sprague-Dawley rats)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of TMP (100 mg, t.i.d. for 16 weeks) in a small cohort of patients with PAH or CTEPH
Number of subjects: 0
Study: 30706426

Group type: EXPERIMENTAL
Intervention: Insulin glargine U300
Number of subjects: 54

Group type: COMPARATOR
Intervention: Insulin degludec U100
Number of subjects: 54
Study: 28887192

Group type: EXPERIMENTAL
Intervention: eCoFit intervention (integrated group sessions and smartphone app)
Number of subjects: 84
Study: 26029694

Group type: EXPERIMENTAL
Intervention: O-PAP (oscillating positive airway pressure)
Number of subjects: 14

Group type: COMPARATOR
Intervention: CPAP (continuous positive airway pressure)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: O-PAP
Number of subjects: 14

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 14
Study: 22911223

Group type: EXPERIMENTAL
Intervention: bupivacaine plus epinephrine 100 μg
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: bupivacaine plus epinephrine 200 μg
Number of subjects: 162

Group type: COMPARATOR
Intervention: bupivacaine
Number of subjects: 162
Study: 21564045

Group type: EXPERIMENTAL
Intervention: Airway Scope
Number of subjects: 140

Group type: COMPARATOR
Intervention: Clarus Video System
Number of subjects: 140
Study: 17991450

Group type: EXPERIMENTAL
Intervention: Intention formation
Number of subjects: 0
Study: 16845866

Group type: EXPERIMENTAL
Intervention: Percutaneous access
Number of subjects: 99

Group type: COMPARATOR
Intervention: Surgical cut-down
Number of subjects: 99
Study: 15198841

Group type: EXPERIMENTAL
Intervention: Weekly fructosamine testing in addition to daily glucose monitoring (Group 1)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care of daily glucose monitoring (Group 2)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Weekly fructosamine testing (Group 1)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care (Group 2)
Number of subjects: 72
Study: 11369660

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 93
Study: 9333659

Group type: EXPERIMENTAL
Intervention: High frequency capsulotomy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Capsulorhexis
Number of subjects: 55
Study: 8282621

Group type: EXPERIMENTAL
Intervention: 8 weeks of progressive bicycle training
Number of subjects: 18
Study: 3567122

Group type: EXPERIMENTAL
Intervention: 4 mg of salbutamol orally five times daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 200
Study: 31062684

Group type: EXPERIMENTAL
Intervention: HIGH-Rasp (20% freeze-dried black raspberries)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LOW-Rasp (10% freeze-dried black raspberries)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference (no fruit ingredients)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LOW-Cran (0.5% cranberry extract)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HIGH-Cran (1% cranberry extract)
Number of subjects: 20
Study: 29797991

Group type: COMPARATOR
Intervention: Experimental group (CRSwNP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (CRSsNP)
Number of subjects: 41
Study: 24818633

Group type: COMPARATOR
Intervention: COBRA therapy (methotrexate 7.5 mg/week, sulfasalazine 2 g/day, with initial prednisolone 60 mg/day)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: COBRA-light therapy (methotrexate increased to 25 mg/week with initial prednisolone 30 mg/day)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Both COBRA and COBRA-light groups
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 162

Group type: COMPARATOR
Intervention: COBRA
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: COBRA-light
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Etanercept addition
Number of subjects: 162
Study: 23278964

Group type: EXPERIMENTAL
Intervention: Minimally invasive fractional bipolar radiofrequency (FRF) treatment
Number of subjects: 100
Study: 21707852

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 18199590

Group type: EXPERIMENTAL
Intervention: Fructose drink (60 g in 500 ml)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glucose drink (60 g in 500 ml)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fructose and Glucose drinks
Number of subjects: 15
Study: 16442153

Group type: EXPERIMENTAL
Intervention: BAY 12‐9566 (tanomastat) 800 mg p.o. b.i.d.
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: BAY 12‐9566 (tanomastat)
Number of subjects: 243
Study: 14615615

Group type: EXPERIMENTAL
Intervention: Anticoagulation (5-10 day course of full-dose low-molecular-weight heparin followed by 3 months of lower-dose low-molecular-weight heparin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inferior vena cava filter placement
Number of subjects: 0
Study: 11739865

Group type: EXPERIMENTAL
Intervention: Liver paste (3.0, 7.5, or 15 mg vitamin A)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Vitamin A supplement (3.0, 7.5, or 15 mg vitamin A)
Number of subjects: 35
Study: 9239992

Group type: EXPERIMENTAL
Intervention: Leucine supplementation (50.0 +/- 3.3 mg/kg body weight per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Leucine supplementation
Number of subjects: 20
Study: 8287270

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standing position
Number of subjects: 19
Study: 3320807

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31529084

Group type: EXPERIMENTAL
Intervention: Oral sugar enriched expressed breastmilk (EBM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: IV dextrose therapy (IVDx)
Number of subjects: 80
Study: 31188728

Group type: EXPERIMENTAL
Intervention: Doxazosin plus finasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Finasteride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy (finasteride plus doxazosin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29069152

Group type: EXPERIMENTAL
Intervention: GIC with 1.25% CHX
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: GIC with 2.5% CHX
Number of subjects: 36

Group type: COMPARATOR
Intervention: GIC
Number of subjects: 36
Study: 26697853

Group type: EXPERIMENTAL
Intervention: Eight-session activity counselling program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (standard pulmonary rehabilitation)
Number of subjects: 80
Study: 23248072

Group type: EXPERIMENTAL
Intervention: Opicapone 10 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Opicapone 25 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Opicapone 100 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Opicapone 200 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Opicapone 400 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Opicapone 800 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Opicapone 1200 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg with high-fat meal
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg fasting
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 21991569

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery with uncinectomy and middle meatal antrostomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Endoscopic sinus surgery with uncinectomy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery with middle meatal antrostomy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (both techniques)
Number of subjects: 30
Study: 18490378

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with sulfamethoxazole/trimethoprim for 2 years
Number of subjects: 100

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with sulfamethoxazole/trimethoprim
Number of subjects: 100
Study: 16567823

Group type: EXPERIMENTAL
Intervention: Telemedicine case management intervention
Number of subjects: 1665

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1665
Study: 12670781

Group type: EXPERIMENTAL
Intervention: cilomilast (15 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: cilomilast + salbutamol (400 microg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: cilomilast + ipratropium bromide (80 microg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: cilomilast + salbutamol + ipratropium
Number of subjects: 21
Study: 11044163

Group type: EXPERIMENTAL
Intervention: Primary resection
Number of subjects: 105

Group type: COMPARATOR
Intervention: Secondary resection
Number of subjects: 105
Study: 8776642

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Platelet-poor plasma (PPP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no APP)
Number of subjects: 60
Study: 1642114

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) 600 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ) 400 mg
Number of subjects: 6
Study: 6299159

Group type: EXPERIMENTAL
Intervention: Steroid/antibiotic combination product (dexamethasone, neomycin, and polymyxin B) for three days prior to surgery and three weeks following surgery
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Steroid/antibiotic combination product
Number of subjects: 23
Study: 30413879

Group type: EXPERIMENTAL
Intervention: QLB type 2 (QLB2)
Number of subjects: 5

Group type: COMPARATOR
Intervention: QLBi
Number of subjects: 5
Study: 27223684

Group type: EXPERIMENTAL
Intervention: Active PHR (HealthTrak) with personalized alerts
Number of subjects: 41

Group type: COMPARATOR
Intervention: Passive PHR
Number of subjects: 41
Study: 25615430

Group type: EXPERIMENTAL
Intervention: Experimental group (21 hr of in-service workshops plus 5 coaching sessions)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Comparison group (workshops alone)
Number of subjects: 121
Study: 24428097

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 136

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 136
Study: 20980923

Group type: EXPERIMENTAL
Intervention: Rotational vibration training (RVT), 12.5 Hz, 12 mm, three sessions per week, for 15 min
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Vertical vibration training (VVT), 35 Hz, 1.7 mm, three sessions per week, for 15 min
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (CG), two blocks of 10 low-intensity gymnastics sessions
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Rotational vibration training (RVT)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Vertical vibration training (VVT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 108
Study: 19073783

Group type: EXPERIMENTAL
Intervention: Videotelephone support service in addition to the 24 hours 'on‐call' service
Number of subjects: 17
Study: 17356258

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 15238902

Group type: EXPERIMENTAL
Intervention: Micronutrient beverage with a meal
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Micronutrient beverage without a meal
Number of subjects: 40
Study: 11573667

Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg ml(-1) in glucose 50 mg ml(-1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ropivacaine 5 mg ml(-1) in glucose 10 mg ml(-1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 9553538

Group type: EXPERIMENTAL
Intervention: Intramedullary hip screw
Number of subjects: 131

Group type: COMPARATOR
Intervention: Sliding hip screw
Number of subjects: 131
Study: 8955861

Group type: EXPERIMENTAL
Intervention: Test preparation of selegiline HCl (4 x 5 mg tablets)
Number of subjects: 25
Study: 2387286

Group type: EXPERIMENTAL
Intervention: Neurotol Slow (SR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tegretol (C)
Number of subjects: 18
Study: 7013971

Group type: EXPERIMENTAL
Intervention: Radiotherapy-chemotherapy (RT & CT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 23
Study: 30893358

Group type: EXPERIMENTAL
Intervention: Treated group (students enrolled in the new language course)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-treated group (students not enrolled in the new language course)
Number of subjects: 0
Study: 28222742

Group type: EXPERIMENTAL
Intervention: 30 g HAM-RS2 muffins (n = 11)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 0 g HAM-RS2 muffins (control; n = 7)
Number of subjects: 18
Study: 26808847

Group type: EXPERIMENTAL
Intervention: Unshod (barefoot) running at 85% of V[Combining Dot Above]O2max
Number of subjects: 14

Group type: COMPARATOR
Intervention: Shod (wearing shoes) running at 85% of V[Combining Dot Above]O2max
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Unshod (barefoot) running at 65% and 75% of V[Combining Dot Above]O2max
Number of subjects: 14

Group type: COMPARATOR
Intervention: Shod (wearing shoes) running at 65% and 75% of V[Combining Dot Above]O2max
Number of subjects: 14
Study: 24289808

Group type: EXPERIMENTAL
Intervention: Fluoride-free toothpaste containing 1.5% arginine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Regular fluoride-containing toothpaste
Number of subjects: 38
Study: 22619083

Group type: EXPERIMENTAL
Intervention: Probable major depression (PHQ-assessed)
Number of subjects: 2053

Group type: EXPERIMENTAL
Intervention: PHQ score of ≥ 10
Number of subjects: 2053

Group type: EXPERIMENTAL
Intervention: Probable major depression (by PHQ-9)
Number of subjects: 2053

Group type: COMPARATOR
Intervention: ACCORD primary composite outcome (cardiovascular death, nonfatal heart attack, or stroke)
Number of subjects: 2053

Group type: COMPARATOR
Intervention: ACCORD microvascular composite outcome
Number of subjects: 2053
Study: 19933407

Group type: EXPERIMENTAL
Intervention: Flow-triggered adaptive servo-ventilation (ASV)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 31
Study: 18056821

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 1801

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1801
Study: 16032784

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (120 mg vitamin C, 30 mg vitamin E, 6 mg beta‐carotene, 100 microg selenium, and 20 mg zinc)
Number of subjects: 12741

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 12741

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12741
Study: 12170041

Group type: EXPERIMENTAL
Intervention: Epidural top-up with 10 ml ropivacaine, 0.75% (group 1, n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (group 2, n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No epidural top-up (group 3, n = 10)
Number of subjects: 30
Study: 9627431

Group type: EXPERIMENTAL
Intervention: Comprehensive prenatal care at a multidisciplinary tertiary clinic
Number of subjects: 175

Group type: COMPARATOR
Intervention: Prenatal care from a variety of area public health clinics
Number of subjects: 175
Study: 8195979

Group type: EXPERIMENTAL
Intervention: HTR polymer bone replacement grafts
Number of subjects: 9

Group type: COMPARATOR
Intervention: AOC bone replacement grafts
Number of subjects: 9
Study: 2454361

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28674740

Group type: EXPERIMENTAL
Intervention: Dynamic Intraligamentary Stabilization (DIS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Primary ACL reconstruction (ACLR)
Number of subjects: 60
Study: 27046472

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich fibrin (PRF) with resorbable collagen membrane
Number of subjects: 16

Group type: COMPARATOR
Intervention: Guided tissue regeneration alone (control group)
Number of subjects: 16
Study: 25525981

Group type: EXPERIMENTAL
Intervention: LG3, LTBP2, Cathepsin L
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NGAL, Cystatin C
Number of subjects: 100
Study: 22460609

Group type: EXPERIMENTAL
Intervention: Lexical-semantic stimulation (LSS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unstructured cognitive stimulation (UCS)
Number of subjects: 40
Study: 20420579

Group type: EXPERIMENTAL
Intervention: High-mono-unsaturated-fatty-acid (HMUFA) diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-saturated-fatty-acid (HSFA) diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-fat/high-complex carbohydrate diet supplemented with 1.24 g/day of long-chain n-3 polyunsaturated fatty acid (LFHCC n-3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-fat/high-complex carbohydrate diet with 1 g/day of sunflower oil high in oleic acid (LFHCC)
Number of subjects: 0
Study: 18686769

Group type: EXPERIMENTAL
Intervention: Scaling/root planing plus test gel application (triclosan 1% + polydimethylsiloxane 13%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scaling/root planing plus control gel application (polydimethylsiloxane 13%)
Number of subjects: 20
Study: 15625365

Group type: COMPARATOR
Intervention: Standard-dose (SD) ifosfamide (1.5 g/m2/d, days 1 through 4) plus doxorubicin (60 mg/m2)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: High-dose (HD) ifosfamide (3.0 g/m2, days 1 through 4) plus doxorubicin (60 mg/m2)
Number of subjects: 79
Study: 12461418

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control (no hydroxyurea)
Number of subjects: 229
Study: 10325738

Group type: EXPERIMENTAL
Intervention: Picolax (sodium picosulphate 10 mg/sachet with magnesium citrate) and clear fluids
Number of subjects: 66

Group type: COMPARATOR
Intervention: Bisacodyl tablets with an unrestricted diet and a phosphate enema
Number of subjects: 66
Study: 8946103

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 3% sodium trimetaphosphate (TMP)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Control toothpaste containing no caries‐preventive agent
Number of subjects: 2500
Study: 1508343

Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoflurane-fentanyl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 6703927

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg ASA + 75 mg DPM, t.d.s.)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High-dose aspirin (300 mg ASA + 75 mg DPM, t.d.s.)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 30775611

Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance™ (GLB-TBI)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Attention control educational support group
Number of subjects: 66
Study: 29719379

Group type: EXPERIMENTAL
Intervention: Orodispersible film (ODF) of tadalafil (20 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Film-coated tablet (FCT) of tadalafil (20 mg)
Number of subjects: 40
Study: 27050538

Group type: EXPERIMENTAL
Intervention: Coflex Interlaminar Stabilization
Number of subjects: 290

Group type: COMPARATOR
Intervention: Fusion
Number of subjects: 290
Study: 25017558

Group type: EXPERIMENTAL
Intervention: 90-day T-Care intervention delivered by a psychiatric nurse practitioner (NP)
Number of subjects: 20